Dr. Vince O’Neill has expertise in therapeutic and diagnostic product development and has held senior leadership roles at global pharmaceutical companies, including Sanofi, Genentech, and GlaxoSmithKline. Most recently, he served as Chief Medical Officer at Mirna Therapeutics and Exosome Diagnostics, where he oversaw global product development and medical affairs. At Genentech and GlaxoSmithKline, he managed the clinical and biomarker development programs of several oncology therapeutic candidates. He was instrumental in the expanded approvals of Genentech’s oncology therapeutics, Avastin® and Tarceva®. At GSK, he oversaw the signal transduction discovery unit and led the first IND application and clinical trial of the MEK inhibitor, MEKINIST®.

Dr. O’Neill has authored several peer-reviewed publications and conference presentations. A member of the Royal College of Physicians, he received his M.D. and B.Sc. in Molecular Pathology from the University of Glasgow, Scotland.